AstraZeneca boosts China presence with FibroGen's anemia drug in $160 million deal
The deal comes at a time when the Anglo-Swedish pharma company is facing a string of investigations in the country, ...
FiercePharma6d
AstraZeneca pays $160M for FibroGen's China unit, regional rights to roxadustat
where the drug is approved under the brand name Evrenzo. Today’s acquisition sees AstraZeneca pay FibroGen an enterprise value of $85 million along with $75 million of net cash that FibroGen ...
pharmaphorum5d
AstraZeneca builds in China as Cosette buys Mayne
The UK-headquartered group has agreed to buy the Chinese subsidiary of FibroGen for around $160 million, claiming ownership of Evrenzo (roxadustat), FibroGen's treatment for anaemia associated ...
FiercePharma5d
Fierce Pharma Asia—Novo Nordisk's fraud accusation; AstraZeneca's China deal; Ono's FDA nod
Last year, AZ recorded $336 million in revenue from the drug, sold as Evrenzo in China, a 22% increase despite generic competition. 3. FDA approves Ono's rare tumor drug from $2.4B Deciphera ...
Business Insider6d
FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million
Company to continue to advance its oncology pipeline, with the initiation of the Phase 2 monotherapy trial of FG-3246 in metastatic castration-resistant prostate cancer (mCRPC) in 2Q 2025 Preliminary ...
Nasdaq6d
FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million
SAN FRANCISCO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the sale of its China subsidiary to AstraZeneca for approximately $160 million. “Today, we ...